发明名称 IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS
摘要 The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5 b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formulae: wherein: J is independently -O- or -NRN1-; RN1, if present, is independently -H or a substituent; RN2 is independently -H or a substituent; Y is independently -CH- or -N-; Q is independently -(CH2)j-M-(CH2)k- wherein: j is independently 0, 1 or 2; k is independently 0, 1, or 2; j+k is 0, 1, or 2; M is independently O-, -S-, -NH-, -NMe-, or -CH2-; each of RP1, RP2, RP5, and RP4 is independently -H or a substituent; and additionally RP1 and RP2 taken together may be CH-CH-CH-CH-; and additionally RP1 and RP5 taken together may be CH-CH-CH-CH-; L is independently: a linker group formed by a chain of 2, 3, or 4 linker moieties; each linker moiety is independently CH2-, -NRN-, -C(-X)-, or -S(-O)2-; either: exactly one linker moiety is -NRN-, or: exactly two linker moieties are -NRN-; either: exactly one linker moiety is -C(-X)-, and no linker moiety is -S(-O)2-, or: exactly one linker moiety is -S(-O)2-, and no linker moiety is -C(-X)-; no two adjacent linker moieties are -NRN-; X is independently -O or -S; each RN is independently -H or a substituent; A is independently: C6-14carboaryl, C5-14heteroaryl, C3-12carbocyclic, C3-12heterocyclic; and is independently unsubstituted or substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.
申请公布号 US2009325945(A1) 申请公布日期 2009.12.31
申请号 US20070298325 申请日期 2007.04.26
申请人 NICULESCU-DUVAZ DAN;SPRINGER CAROLINE JOY;MARAIS RICHARD MALCOLM;DIJKSTRA HARMEN;MENARD DELPHINE;NICULESCU-DUVAZ ION;DAVIES LAWRENCE;NOURRY ARNAUD 发明人 NICULESCU-DUVAZ DAN;SPRINGER CAROLINE JOY;MARAIS RICHARD MALCOLM;DIJKSTRA HARMEN;MENARD DELPHINE;NICULESCU-DUVAZ ION;DAVIES LAWRENCE;NOURRY ARNAUD
分类号 A61K31/541;A61K31/437;C07D471/02 主分类号 A61K31/541
代理机构 代理人
主权项
地址